Vaxcyte stock reports OPUS-1 success after a 9.65 percent drop

Published on 10/07/2026 at 05:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Vaxcyte stock traded at USD 66.70 on October 6, 2026, while VAX-31 met 20 of 20 PCV20 comparisons. A USD 1 billion financing adds dilution risk.

PCVX, US92243G1085, Illustration mit AI erstellt.

Vaxcyte, Inc. (ISIN US92243G1085) was last at USD 66.70 on Nasdaq on October 6, 2026, down 9.65 percent from the prior session. The move followed a major clinical update and a proposed USD 1.0 billion financing announced as the company prepares its next development steps.

OPUS-1 clears key endpoints

According to Vaxcyte on October 5, 2026, its VAX-31 candidate met all prespecified primary immunogenicity endpoints in the pivotal adult OPUS-1 Phase 3 trial. The trial enrolled 4,047 participants, including 3,572 adults aged 50 and older and 475 adults aged 18 to 49.

The comparison with existing vaccines is central to the result. VAX-31 met the noninferiority threshold in 20 of 20 serotype comparisons shared with Pfizer's PCV20 and in 17 of 19 comparisons shared with Merck's PCV21; the two remaining PCV21 comparisons met the historical threshold above 0.5, according to the company release.

Funding brings dilution risk

On October 5, 2026, Vaxcyte announced proposed offerings of USD 500 million in common stock and pre-funded warrants plus USD 500 million of convertible senior notes due 2032. Underwriters may receive options for an additional USD 75 million of each security, so the transaction could expand beyond the initial USD 1.0 billion.

The proceeds are intended to support VAX-31 trials, manufacturing scale-up and commercial preparations. For shareholders, the trade-off is direct: the equity and warrant component can dilute ownership, while the notes add a future conversion and debt obligation before either offering is completed.

Losses remain substantial

Vaxcyte's clinical progress comes alongside heavy spending. In the second quarter of 2026, operating expenses reached USD 302.8 million versus USD 226.2 million in the second quarter of 2025, while the six-month net loss was USD 604.9 million, Yahoo Finance reported with reference to the August 5, 2026 results. Cash and investments stood at USD 2.51 billion at the end of June, giving the financing plan a clear runway purpose rather than a revenue-growth rationale.

The next clinical checkpoints are OPUS-2 and OPUS-3, for which Vaxcyte expects results in the first half of 2027. The company also plans a biologics license application submission in the first half of 2028, subject to further clinical and regulatory progress.

Analyst targets stay above market

Analyst expectations remain materially higher than the October 6 price. Investing.com reported on October 6, 2026, that BofA Securities raised its target from USD 130 to USD 146 while retaining a Buy rating. The target lies 118.9 percent above the USD 66.70 price.

MarketBeat reported on October 6, 2026, that six analysts rated Vaxcyte Buy, one rated it Hold and one rated it Sell, producing a Moderate Buy consensus with an average target of USD 108.60. That average target lies 62.8 percent above the October 6 price, while the financing announcement explains why the market response was weaker than the clinical headline.

Stock remains below yearly high

Vaxcyte stock was last at USD 66.70 on Nasdaq at 4:00 p.m. ET on October 6, 2026. The session range was USD 63.90 to USD 73.39, the 52-week range was USD 39.87 to USD 90.75, and market capitalization was USD 9.6 billion.